<table frame="hsides" xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 2. Treatment Regimens Used in Phase 3 Studies of Patients with Early Breast Cancer</caption>
<thead>
<tr><td align="left" valign="top"></td><td align="left" valign="top">Treatment Groups</td><td align="left" valign="top">Agent</td><td align="left" valign="top">Regimen</td></tr>
</thead>
<tfoot>
<tr><td align="left" colspan="4" valign="top"><sup>1</sup>In women who underwent lumpectomy, breast irradiation was to be administered after completion of study chemotherapy.</td></tr>
<tr><td align="left" colspan="4" valign="top"><sup>2</sup>Patients also received prophylactic antibiotic therapy with trimethoprim-sulfamethoxazole or fluoroquinolone for the duration of their chemotherapy.</td></tr>
<tr><td align="left" colspan="4" valign="top"><sup>3</sup>All women were to receive breast irradiation after the completion of chemotherapy.</td></tr>
</tfoot>
<tbody>
<tr><td align="left" rowspan="6" valign="top">MA-5<sup>1</sup> N=716</td><td align="left" valign="top"><content stylecode="bold">CEF-120</content> (total, 6 cycles)<sup>2</sup> N=356</td><td align="left" valign="top">Cyclophosphamide </td><td align="left" valign="top">75 mg/m<sup>2</sup> PO, d 1 to 14, q 28 days</td></tr>
<tr><td align="left" valign="top"></td><td align="left" valign="top">Epirubicin Hydrochloride Injection </td><td align="left" valign="top">60 mg/m<sup>2</sup> IV, d 1 &amp; 8, q 28 days </td></tr>
<tr><td align="left" valign="top"></td><td align="left" valign="top">Fluorouracil</td><td align="left" valign="top">500 mg/m<sup>2</sup> IV, d 1 &amp; 8, q 28 days </td></tr>
<tr><td align="left" valign="top"><content stylecode="bold">CMF</content> (total, 6 cycles) N=360</td><td align="left" valign="top">Cyclophosphamide</td><td align="left" valign="top">100 mg/m<sup>2</sup> PO, d 1 to 14, q 28 days</td></tr>
<tr><td align="left" valign="top"></td><td align="left" valign="top">Methotrexate</td><td align="left" valign="top">40 mg/m<sup>2</sup> IV, d 1 &amp; 8, q 28 days</td></tr>
<tr><td align="left" valign="top"></td><td align="left" valign="top">Fluorouracil</td><td align="left" valign="top">600 mg/m<sup>2</sup> IV, d 1 &amp; 8, q 28 days</td></tr>
<tr><td align="left" rowspan="5" valign="top">GFEA-05<sup>3</sup> N=565</td><td align="left" valign="top"><content stylecode="bold">FEC-100</content> (total, 6 cycles) N=276</td><td align="left" valign="top">Fluorouracil</td><td align="left" valign="top">500 mg/m<sup>2</sup> IV, d 1, q 21 days</td></tr>
<tr><td align="left" valign="top"></td><td align="left" valign="top">Epirubicin Hydrochloride Injection</td><td align="left" valign="top">100 mg/m<sup>2</sup> IV, d 1, q 21 days</td></tr>
<tr><td align="left" valign="top"></td><td align="left" valign="top">Cyclophosphamide</td><td align="left" valign="top">500 mg/m<sup>2</sup> IV, d 1, q 21 days </td></tr>
<tr><td align="left" valign="top"><content stylecode="bold">FEC-50</content> (total, 6 cycles) N=289 </td><td align="left" valign="top">Fluorouracil</td><td align="left" valign="top">500 mg/m<sup>2</sup> IV, d 1, q 21 days</td></tr>
<tr><td align="left" valign="top">Tamoxifen 30 mg daily x 3 years,</td><td align="left" valign="top">Epirubicin Hydrochloride Injection</td><td align="left" valign="top">50 mg/m<sup>2</sup> IV, d 1, q 21 days</td></tr>
<tr><td align="left" valign="top"></td><td align="left" valign="top">postmenopausal women, any receptor status</td><td align="left" valign="top">Cyclophosphamide</td><td align="left" valign="top">500 mg/m<sup>2</sup> IV, d 1, q 21 days</td></tr>
</tbody>
</table>